A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Confirmed NSCLC * Stage IV disease at the time of study entry * Measurable disease at the time of study entry * Resolution to Grade ≤ 1 Adverse Events, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (except alopecia) * Adequate hematologic function, hepatic function, renal function and coagulation function * If sexually active, must be post-menopausal, surgically sterile, or using effective contraception; and agrees to use adequate contraception during the study period and for up to 6 months after the last dose of study medication * Female participants of childbearing potential must have a negative serum pregnancy test Exclusion Criteria: * Has cirrhosis at a level of Child-Pugh B (or worse), or cirrhosis and a history of hepatic encephalopathy, or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis * Tumor wholly or partially contains small cell lung cancer * Untreated central nervous system (CNS) metastases, eligible if they are clinically stable with regard to neurologic function, off all steroids after cranial irradiation at least 2 weeks prior or after surgical resection performed at least 4 weeks prior to randomization * Concurrent active malignancy other than adequately treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix. A participant with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for ≥ 3 years * Received prior therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) * Receiving concurrent treatment with other anticancer therapy * Has received previous chemotherapy for Stage IV NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization) * Has radiologically documented evidence of major blood vessel invasion or encasement by cancer * Has undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions) * Ongoing or active infection * History of significant neurological or psychiatric disorders * Experienced clinically relevant coronary artery disease, myocardial infarction within 6 months prior to randomization, uncontrolled congestive heart failure, or symptomatic poorly controlled arrhythmia * Poorly-controlled hypertension * Experienced any serious Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry * Receiving chronic daily treatment with aspirin (\> 325 mg/day) or other known inhibitors of platelet function * Serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization * Major surgery within 28 days prior the first dose of study medication, or subcutaneous venous access device placement within 7 days prior to randomization * Elective or a planned major surgery * Pregnant or lactating * Any other serious uncontrolled medical disorders or psychological conditions * Allergy / history of hypersensitivity reaction to any of the treatment components * History of drug abuse